Brief: Active Biotech Receives U.S. Patent For Laquinimod In Eye Disorders

Active Biotech AB publ

24/10/2022 07:33

Oct 24 (Reuters) - Active Biotech AB publ  ACTI.ST :
    * ACTIVE BIOTECH FURTHER STRENGTHENS THE PATENT PROTECTION
FOR
LAQUINIMOD IN EYE DISORDERS WITH A GRANTED PATENT IN US
    * US PATENT OFFICE (USPTO) HAS ISSUED A DECISION TO GRANT
ACTIVE
BIOTECH'S PATENT RELATED TO USE OF LAQUINIMOD AS TREATMENT OF
EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARIZATION
    * PATENT WILL BE ISSUED ON 25 OCTOBER, 2022, UNDER PATENT
NUMBER
11,478,465 AND PROVIDES PROTECTION AND MARKET EXCLUSIVITY IN
THIS FIELD OF USE UNTIL 2040
    * PATENT COVERS MEDICAL USE OF DES-ETHYL LAQUINIMOD FOR
TREATMENT
OF SIGHT-THREATENING EYE DISORDERS

Source text for Eikon:  ID:nMFN1hgPKK 
Further company coverage:  ACTI.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))